Clinicians must recognize situations in which formal echocardiography should be pursued as well as the inherent limitations of focused cardiac ultrasonography.
The risk of sudden cardiac death was present across all strata of left ventricular ejection fraction and was related to the use of cocaine, lower use of beta-blockers, lower CD4, and nonsuppressed viral load.
Novartis announced results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan in HFpEF.
Investigators analyzed the safety and efficacy of high-dose spironolactone to treat select patients with acute decompensated heart failure.
Higher plasma eicosapentaenoic acid was significantly associated with reduced risk for heart failure.
The excess risk for heart failure associated with diabetes is significantly greater in women than men.
The FDA has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization in patients with chronic heart failure.
Patients with nonspecific intraventricular conduction delay and QRS duration <150 ms orright bundle branch block may not benefit from cardiac resynchronization therapy with defibrillator, compared with implantable cardioverter-defibrillator therapy alone.
Revascor is a cell therapy that consists of 150 million allogeneic mesenchymal precursor cells and is delivered as a single intra-myocardial injection.
Patients with heart failure, severe pulmonary hypertension, and a preserved ejection fraction of ≥50% had a worse prognosis when compared with other patients with heart failure and severe pulmonary hypertension.